Using Immune Checkpoint Inhibitors in Lung Cancer

Area of Science:

• Oncology
• Immunology

Background:

• Immune checkpoint inhibitors (ICIs) are transforming lung cancer therapy.
• Two anti-programmed death 1 (PD-1) agents are approved for advanced or metastatic non-small-cell lung cancer (NSCLC) second-line treatment.

Purpose of the Study:

• To review the current landscape and future directions of immune checkpoint inhibition in lung cancer.
• To highlight ongoing research evaluating ICIs in various combinations and settings.

Main Methods:

• Review of current clinical practice and ongoing clinical trials.
• Discussion of translational research for biomarker discovery.

Main Results:

• Increased clinical utilization of anti-PD-1 ICIs in NSCLC.
• Active investigation of ICIs in combination with chemotherapy, radiation, and targeted therapies.
• Exploration of ICIs in small-cell lung cancer and diverse NSCLC stages.

Conclusions:

• Immune checkpoint inhibition represents a significant advancement in lung cancer treatment.
• Further research is crucial to optimize efficacy, safety, and cost-effectiveness.
• Biomarker discovery is key to refining patient selection and treatment strategies.